ROCKVILLE, Md., Oct. 30, 2018 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE American: SYN), a late-stage clinical company
developing therapeutics that preserve the microbiome to protect and
restore the health of patients, announced today that the Company
intends to release its operational highlights and financial results
for the quarter ended September 30,
2018 on Thursday, November 8,
2018, and to host a conference call the same day at
4:30 p.m. EDT. The dial-in
information for the call is as follows:
U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280
Participants are asked to dial in 15 minutes before the start of
the call to register. The call will also be webcast over the
Internet at https://www.webcaster4.com/Webcast/Page/1096/28046. An
archived replay of the call will be available for approximately
ninety (90) days at the same URL,
https://www.webcaster4.com/Webcast/Page/1096/28046 beginning
approximately one hour after the call's conclusion.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage
clinical company developing therapeutics that preserve the
microbiome to protect and restore the health of patients. The
Company's lead candidates poised for Phase 3 development are: (1)
SYN-004 (ribaxamase) which is designed to protect the gut
microbiome from the effects of certain commonly used intravenous
(IV) beta-lactam antibiotics for the prevention of C.
difficile infection (CDI), overgrowth of pathogenic organisms
and the emergence of antimicrobial resistance (AMR), and (2)
SYN-010 which is intended to reduce the impact of methane producing
organisms in the gut microbiome to treat an underlying cause of
irritable bowel syndrome with constipation (IBS-C). The Company's
preclinical pursuits include an oral formulation of the enzyme
intestinal alkaline phosphatase (IAP) to treat both local GI and
systemic diseases as well as monoclonal antibody therapies for the
prevention and treatment of pertussis, and novel discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-third-quarter-2018-operational-highlights-and-financial-results-on-november-8-2018-300740724.html
SOURCE Synthetic Biologics, Inc.